MediImg Co., Ltd.
Leveraging Hemodynamic (SIG) Biomarkers and VINT Technology, We Have Published Numerous Research Papers in Leading Domestic and International Academic Journals and Hold Key Patents to Establish a New Standard in Cerebrovascular Diagnosis.
MediImg Co., Ltd.
Leveraging Hemodynamic (SIG) Biomarkers and VINT Technology,
We Have Published Numerous Research Papers in Leading Domestic and International Academic Journals
and Hold Key Patents to Establish a New Standard in Cerebrovascular Diagnosis.
MediImg Co., Ltd. | Est. 2018
Business License No. : 313-87-00931
Head Office: #508, SBA Hub, Mapo-gu, Seoul, Korea
R&D Center: #6, 2F, Seoul National University Hospital Healthcare Innovation Park, Bundang, Gyeonggi-do, Korea
TEL : (+82) 02-484-5773 | FAX : (+82) 02-6499-6448
E-mail : info@mediimg.com
FDA 510K Approval Date : October 15, 2024
Copyright © 2025 MEDIIMG Co., Ltd. All rights reserved.
Approved by the MFDS
MediImg Co., Ltd. | Est. 2018
Business License No. : 313-87-00931
Head Office: #508, SBA Hub, Mapo-gu, Seoul, Korea
R&D Center: #6, 2F, Seoul National University Hospital Healthcare Innovation Park,
Bundang, Gyeonggi-do, Korea
TEL : (+82) 02-484-5773 | FAX : (+82) 02-6499-6448 | E-mail｜info@mediimg.com
FDA 510K Approval Date : October 15, 2024
Approved by the MFDS
Copyright © 2025 MEDIIMG Co., Ltd. All rights reserved.
